News

UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expa…

Home’s primary endpoint of being well tolerated in the at-home treatment of agitation episodes in patients with bipolar ...